Sign in

    Derek Johnson

    Biotech Equity Research Senior Associate at Guggenheim Partners

    Derek Johnson is a Biotech Equity Research Senior Associate at Guggenheim Partners, specializing in biotechnology sector analysis with a focus on individual companies like InflaRx. His coverage includes providing insights and earnings call questions for biotech firms, and he has been noted for his involvement in research activity related to these companies. Derek joined Guggenheim Partners following prior experience at other investment firms and has developed expertise in equity research since starting his career in finance. He holds professional credentials relevant to his analyst role and has demonstrated a strong analytical skill set within the biotech space.

    Derek Johnson's questions to InflaRx (IFRX) leadership

    Derek Johnson's questions to InflaRx (IFRX) leadership • Q3 2019

    Question

    Derek Johnson from Guggenheim Partners asked if any biomarker analysis had been conducted to identify patient subsets likely to respond, potentially to exclude nonresponders from future trials. He also requested clarification on the data in Slide 12, which appeared to show a number of IHS-4 responders in the original placebo group.

    Answer

    Executive Niels Riedemann explained that while the company is actively working on a biomarker that tracks treatment response, analysis to predict responders upfront has not been conducted yet. Regarding Slide 12, he clarified that the mean IHS-4 response shown for the placebo-transitioned group was skewed by a few patients with an extremely good response and directed attention to Slide 7 for a more representative view of the overall placebo group's performance, highlighting the risk of being fooled by small patient numbers.

    Ask Fintool Equity Research AI